KORTHOS / ECOSYSTEM / PRODUCT

EksoNR

About

About EksoNR

EksoNR powers the hip and knee joints to support sit-to-stand, walking, stand-to-sit and pre-gait exercises on solid, dry, level surfaces. A trained clinician configures fixed or adaptive assistance for one or both legs, while the patient initiates steps through weight shift or an external controller. The device records session measures for clinical review.

The system fits adults from 1.52 to 1.93 metres and up to 100 kilograms; its own mass is approximately 24.9 kilograms with batteries. EksoNR is restricted to certified rehabilitation centres and requires supervision plus an assistive device during use. FDA-cleared populations include spinal cord injury, stroke, acquired brain injury and multiple sclerosis, subject to the full labelled indications and patient screening.

Timeline

  • Wandercraft completes acquisition of Ekso Bionics operating business

    2026-10-01 - Acquisition - Atalante X and EksoNR together support patients at more than 700 rehabilitation centers worldwide. Wandercraft intends to keep supporting Atalante X, EksoNR, Eve and Indego Personal. Both boards unanimously approved the transaction, combining Wandercraft’s EMEA position with Ekso’s U.S. clinical and commercial reach.

    Source
  • EksoNR receives FDA clearance for acquired brain injury rehabilitation

    2020-06-15 - Regulatory - The clearance expanded EksoNR beyond earlier stroke and spinal cord injury indications. The system is a robotic exoskeleton used in clinical rehabilitation settings. The approval supports EksoNR's path toward fielded use in robot manipulation, haptics or human-assistive robotics workflows.

    Source

Context

Comparable Systems